Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL

NCT05594784 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

79

Enrollment

OTHER

Sponsor class

Conditions

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Interventions

DRUG: Olverembatinib
DRUG: Venetoclax
DRUG: prednisone
DRUG: Vincristine

Sponsor

Institute of Hematology & Blood Diseases Hospital, China